Pamapimod

• CAT Number: I003588
• CAS Number: 449811-01-2
• Molecular Formula: C₁₉H₂₀F₂N₄O₄
• Molecular Weight: 406.38
• Purity: ≥95%
• Target: p38
• Solubility: DMSO ≥ 34 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C19H20F2N4O4/c1-25-17-11(10-22-19(24-17)23-13(4-6-26)5-7-27)8-16(18(25)28)29-15-3-2-12(20)9-14(15)21/h2-3,8-10,13,26-27H,4-7H2,1H3,(H,22,23,24)
• InChIKey: JYYLVUFNAHSSFE-UHFFFAOYSA-N
• SMILES: CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC(CCO)CCO

Pamapimod (CAT: I003588) is a novel inhibitor of p38 mitogen-activated protein kinase (MAPK). By specifically targeting and inhibiting the activity of p38 MAPK, pamapimod modulates intracellular signaling pathways involved in inflammation and immune response. This inhibition of p38 MAPK activity has the potential to suppress the production of pro-inflammatory cytokines and other mediators involved in various inflammatory diseases. Pamapimod represents a promising therapeutic approach for the treatment of conditions where dysregulated p38 MAPK signaling plays a role, such as autoimmune disorders and chronic inflammatory conditions.

Reference

1: Zhang X, Fettner S, Winter E, Masjedizadeh M, Hisoire G. Metabolism and
excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects.
Int J Clin Pharmacol Ther. 2011 Jun;49(6):345-52. PubMed PMID: 21612741.

2: Doggrell SA, Christensen AM. Does the p38 MAP kinase inhibitor pamapimod have
potential for the treatment of rheumatoid arthritis? Expert Opin Pharmacother.
2010 Oct;11(14):2437-42. doi: 10.1517/14656566.2010.507631. PubMed PMID:
20666701.

3: Zhang X, Huang Y, Navarro MT, Hisoire G, Caulfield JP. A proof-of-concept and
drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with
methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol. 2010
Sep;50(9):1031-8. doi: 10.1177/0091270009357433. Epub 2010 Jan 25. PubMed PMID:
20100913.

4: Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW,
Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning
AM, Peng SL, Goldstein DM, Wong BR. Pamapimod, a novel p38 mitogen-activated
protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J
Pharmacol Exp Ther. 2008 Dec;327(3):610-9. doi: 10.1124/jpet.108.139006. Epub
2008 Sep 5. PubMed PMID: 18776065.